Cargando…
Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer
The incidence of gastric cancer is increasing year by year. Most gastric cancers are already in the advanced stage with poor prognosis when diagnosed, which means the current treatment is not satisfactory. Angiogenesis is an important link in the occurrence and development of tumors, and there are m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295723/ https://www.ncbi.nlm.nih.gov/pubmed/37384288 http://dx.doi.org/10.3389/fonc.2023.1148131 |
_version_ | 1785063489030586368 |
---|---|
author | Xu, Donghan Luo, Yehao Wang, Peng Li, Jiaxin Ma, Linrui Huang, Jie Zhang, Hao Yang, Xiaoman Li, Liqi Zheng, Yuhong Fang, Gang Yan, Peiyu |
author_facet | Xu, Donghan Luo, Yehao Wang, Peng Li, Jiaxin Ma, Linrui Huang, Jie Zhang, Hao Yang, Xiaoman Li, Liqi Zheng, Yuhong Fang, Gang Yan, Peiyu |
author_sort | Xu, Donghan |
collection | PubMed |
description | The incidence of gastric cancer is increasing year by year. Most gastric cancers are already in the advanced stage with poor prognosis when diagnosed, which means the current treatment is not satisfactory. Angiogenesis is an important link in the occurrence and development of tumors, and there are multiple anti-angiogenesis targeted therapies. To comprehensively evaluate the efficacy and safety of anti-angiogenic targeted drugs alone and in combination against gastric cancer, we systematically searched and sorted out relevant literature. In this review, we summarized the efficacy and safety of Ramucirumab, Bevacizumab, Apatinib, Fruquintinib, Sorafenib, Sunitinib, Pazopanib on gastric cancer when used alone or in combination based on prospective clinical trials reported in the literature, and sorted response biomarkers. We also summarized the challenges faced by anti-angiogenesis therapy for gastric cancer and available solutions. Finally, the characteristics of the current clinical research are summarized and suggestions and prospects are raised. This review will serve as a good reference for the clinical research of anti-angiogenic targeted drugs in the treatment of gastric cancer. |
format | Online Article Text |
id | pubmed-10295723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102957232023-06-28 Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer Xu, Donghan Luo, Yehao Wang, Peng Li, Jiaxin Ma, Linrui Huang, Jie Zhang, Hao Yang, Xiaoman Li, Liqi Zheng, Yuhong Fang, Gang Yan, Peiyu Front Oncol Oncology The incidence of gastric cancer is increasing year by year. Most gastric cancers are already in the advanced stage with poor prognosis when diagnosed, which means the current treatment is not satisfactory. Angiogenesis is an important link in the occurrence and development of tumors, and there are multiple anti-angiogenesis targeted therapies. To comprehensively evaluate the efficacy and safety of anti-angiogenic targeted drugs alone and in combination against gastric cancer, we systematically searched and sorted out relevant literature. In this review, we summarized the efficacy and safety of Ramucirumab, Bevacizumab, Apatinib, Fruquintinib, Sorafenib, Sunitinib, Pazopanib on gastric cancer when used alone or in combination based on prospective clinical trials reported in the literature, and sorted response biomarkers. We also summarized the challenges faced by anti-angiogenesis therapy for gastric cancer and available solutions. Finally, the characteristics of the current clinical research are summarized and suggestions and prospects are raised. This review will serve as a good reference for the clinical research of anti-angiogenic targeted drugs in the treatment of gastric cancer. Frontiers Media S.A. 2023-06-12 /pmc/articles/PMC10295723/ /pubmed/37384288 http://dx.doi.org/10.3389/fonc.2023.1148131 Text en Copyright © 2023 Xu, Luo, Wang, Li, Ma, Huang, Zhang, Yang, Li, Zheng, Fang and Yan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xu, Donghan Luo, Yehao Wang, Peng Li, Jiaxin Ma, Linrui Huang, Jie Zhang, Hao Yang, Xiaoman Li, Liqi Zheng, Yuhong Fang, Gang Yan, Peiyu Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer |
title | Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer |
title_full | Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer |
title_fullStr | Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer |
title_full_unstemmed | Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer |
title_short | Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer |
title_sort | clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295723/ https://www.ncbi.nlm.nih.gov/pubmed/37384288 http://dx.doi.org/10.3389/fonc.2023.1148131 |
work_keys_str_mv | AT xudonghan clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT luoyehao clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT wangpeng clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT lijiaxin clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT malinrui clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT huangjie clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT zhanghao clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT yangxiaoman clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT liliqi clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT zhengyuhong clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT fanggang clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer AT yanpeiyu clinicalprogressofantiangiogenictargetedtherapyandcombinationtherapyforgastriccancer |